Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.
Telix Pharmaceuticals has reported the lapse of 1,014,318 share appreciation rights (SARs) under its equity incentive arrangements, after the performance or vesting conditions attached to these rights were not met or became incapable of being satisfied. The cessation of these SARs, effective 16 March 2026, reduces Telix’s pool of potential dilutive securities, slightly tightening its issued capital structure and potentially affecting the future value of remaining equity-based incentives for employees and executives.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$32.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company listed on the ASX under the code TLX. The company focuses on developing and commercialising radiopharmaceutical products for the diagnosis and treatment of cancer and other serious diseases, targeting both domestic and international healthcare markets.
Average Trading Volume: 2,879,118
Technical Sentiment Signal: Sell
Current Market Cap: A$3.72B
See more data about TLX stock on TipRanks’ Stock Analysis page.